8.70
-1.81%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About KPC Pharmaceuticals
Its shares trade on Shanghai under the ticker 600422.SS. It has been listed since 6 December 2000. In the fiscal year to 31 December 2025, it reported revenue of CN¥6.58bn and net income of CN¥349.9m. At that date it held total assets of CN¥11.77bn and shareholders' equity of CN¥5.36bn.
KPC Pharmaceuticals, Inc. engages in the research & development, manufacture, sale, commercial wholesale, and international marketing of drugs. The company is headquartered in Kunming, Yunnan. The company went IPO on 2000-12-06. The firm's main products include natural herbal medicines, traditional Chinese medicines and chemical synthetic drugs, such as central nervous system drugs, cardiovascular and cerebrovascular drugs, anti-parasitic drugs, anti-microbial drugs, anti-gout drugs, hormones and endocrine drugs, hemorrhoids medicines and anti-inflammatory drugs, among others. The firm is also engaged in the production of health products and provision of medical services.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 6 Dec 2000
- Employees
- 5,322
- Website
- kpc.com.cn ↗
Leadership
Pay as last reported
- Mr. Wenduo WuChairman of the Board, since 2025
- Mr. Wei YanPresident, Vice Chairman of the Board, since 2023
- Mr. Hongshen LiVice Chairman of the Board, since 2024
- Mr. Zhiqiang SunChief Financial Officer, Finance Director
- Ms. Li MengExecutive Vice PresidentCN¥587,800
- Mr. Junfeng LiuSenior Vice PresidentCN¥640,700
- Ms. Mengxun ZhangVice President, General Counsel, Secretary of the BoardCN¥577,600
- Mr. Tong GaoVice President
- Mr. Lichun LiVice President
- Mr. Cheng SunVice President
- Mr. Kai XiVice President
- Mr. Ting GuoDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Kunming, Yunnan, with 5,322 employees.
- Offers a diverse product portfolio including natural herbal medicines and traditional Chinese medicines.
- Engages in research & development, manufacturing, and international marketing of drugs.
Weaknesses
- No specific weaknesses mentioned in the provided information.
- No details on financial performance or market share provided.
- No information on competitive advantages or unique selling points.
Opportunities
- Expansion into international markets through international marketing activities.
- Growth potential in health products and medical services sectors.
- Opportunities in the pharmaceutical industry due to diverse product offerings.
Threats
- No specific threats mentioned in the provided information.
- No details on regulatory challenges or market competition provided.
- No information on potential risks to the business model.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.